BeiGene Investing Activities - Other 2014-2024 | ONC
BeiGene annual/quarterly investing activities - other history and growth rate from 2014 to 2024. Investing activities - other can be defined as the net amount of items a company reports that are too small to report separately. Additionally, this field holds the sum of items a company reports that cannot be assigned to any other standardized field in the investing activities section of the Cash Flows Statement
- BeiGene investing activities - other for the quarter ending September 30, 2024 was $-0.053B, a 71.82% increase year-over-year.
- BeiGene investing activities - other for the twelve months ending September 30, 2024 was $-0.171B, a 12.77% decline year-over-year.
- BeiGene annual investing activities - other for 2023 was $-0.015B, a 89.56% decline from 2022.
- BeiGene annual investing activities - other for 2022 was $-0.144B, a 1590.18% increase from 2021.
- BeiGene annual investing activities - other for 2021 was $-0.009B, a 92.38% decline from 2020.
BeiGene Annual Investing Activities - Other
(Millions of US $) |
| 2023 |
$-15 |
| 2022 |
$-144 |
| 2021 |
$-9 |
| 2020 |
$-112 |
| 2019 |
$-69 |
| 2018 |
$-70 |
| 2017 |
$20 |
| 2016 |
$ |
| 2015 |
$ |
| 2014 |
$-2 |
| 2013 |
$ |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
